The Scientist Behind Psychedelic Receptor Research

Pharmacologist Bryan L. Roth has spent roughly 40 years mapping the brain receptors psychedelics activate, work that began almost alone in the field and now anchors a DARPA-funded push to build psychedelic drugs without the trip. In this long interview, he explains why salvia hits a completely different receptor than LSD or psilocybin, why ibogaine and DMT resist explanation, and why he sees choosing the right target, not chemistry, as drug discovery's real bottleneck.

From Childhood to a Career "by Accident"

Roth's mother was diagnosed with schizophrenia when he was five or six; a few years later his sister took LSD and made the front page of the local paper, sending the Montana teenager to a library book calling LSD a "model psychosis." A PhD in opioid receptors led to an NIH postdoc under Erminio Costa, who assigned him the obscure 5-HT2 receptor just as clozapine turned out to block it and LSD turned out to activate it, "falling into the field by accident." For most of the roughly 40 years since, only a handful of scientists, including Dave Nichols and Richard Glennon, studied psychedelic receptor pharmacology, he says, and grants had to say "hallucinogen," not "psychedelic," until three 2016 psilocybin papers reignited the field.

Two Stories That Changed His Mind

Roth stayed skeptical of psychedelics' therapeutic value, he says, until a scientist friend visited a legal psilocybin clinic in Australia, and until a Vietnam veteran described guided psilocybin and iboga-derived ibogaine sessions that helped him past severe combat PTSD, at a point, in the veteran's words, where "the gun was in his mouth." Roth, a trained psychiatrist, calls these anecdotes, not evidence, but says they happen enough that "you can't ignore it."

Ibogaine and the Kappa Receptor's Buried History

Ibogaine, a plant compound used historically by African healers, is not technically a psychedelic in Roth's terms since it does not act on the 5-HT2A receptor; he classes it as an "oneirogen," alongside salvia's salvinorin A, and links its effects to the kappa opioid receptor, known since the 1970s to be "psychotomimetic," a fact he says the opioid field has downplayed since it undercuts kappa's value as a painkiller. His lab found no other brain targets for ibogaine; sessions run 12 to 24 hours, and a cardiac-channel effect can cause fatal arrhythmias, requiring licensed, EKG-monitored care, never recreational use. His own lab's finding that salvinorin A is an extremely selective kappa agonist surprised even Roth at first; none of the classic psychedelics (LSD, psilocybin, DMT) touch the kappa receptor at all.

The Claustrum: A Shared Hub for Reality Construction

Kappa and 5-HT2A receptors both concentrate in the claustrum, long thought to be a hub for perception. Roth's model: psychedelics disrupt layer-five cortical and claustrum neurons that normally filter sensory input into a coherent reality; firing asynchronously, those neurons push the brain to build experience from internally generated signals instead. Ketamine and scopolamine affect the same system, he says, though how kappa agonists do the same stays unknown to him. See Psylopedia's neuroplasticity primer.

Why It Feels Meaningful, and Why DMT Still Baffles Him

Roth flags a real puzzle: psychedelic experiences often rank among life's most meaningful, a quality tied to norepinephrine, yet these drugs barely touch that system. DMT is harder still: people describe an "alternative universe" that feels more real than reality, which Roth compares to how psychosis makes delusions feel more real than the world. Salvia tends toward bizarre but more human-scale distortions, like a reported case of someone experiencing themselves as "plaid on a wall," rather than DMT's alien geometry.

Funding, DARPA, and Building a Trip-Free Psychedelic

Roth calls the roughly $50 million floated in a recent psychedelic-research executive order too little for even a small clinical trial, noting a Phase 3 trial of lumateperone, which he co-developed, cost several hundred million. His non-hallucinogenic psychedelic work, he admits, began not from concern for people vulnerable to psychosis but from a DARPA grant: after his lab solved an LSD-bound receptor structure, he floated the idea at a talk, and DARPA, drawn by high psychiatric-disability rates in the military, funded it with 26.9 million dollars. The method, "biased agonism," steers the 5-HT2A receptor toward its Gq pathway, tied to psychedelics' neuroplasticity effects, and away from the beta-arrestin pathway tied to their hallucinogenic effects. After roughly 1,000 candidates over five years, the resulting molecules act like antidepressants in mice, an unproven hypothesis in humans.

Who Should Be Cautious, and What AI Can (and Cannot) Fix

Roth says people with a personal or family history of schizophrenia, bipolar disorder, or borderline personality disorder should generally avoid psychedelics, and flags hallucinogen persisting perceptual disorder, a rare, sometimes lifelong visual condition with no treatment. Asked if he has taken psychedelics himself, he declines to answer. On AI, he says computational chemistry can now screen roughly a trillion candidate compounds and has largely solved safe drug design; the harder problem is choosing the right target, since only about 100 of the genome's 26,000 targets have ever been drugged.

Key takeaways

• ●Bryan L. Roth has studied psychedelic receptor biology for roughly 40 years, much of it as one of only a handful of scientists in the field.
• ●His lab found salvinorin A, salvia's active compound, to be a highly selective kappa receptor agonist, unlike LSD, psilocybin, and DMT, which do not touch that receptor.
• ●Roth still cannot fully explain how ibogaine works and says it carries a real cardiac risk that requires licensed, EKG-monitored supervision, never recreational use.
• ●Roth's DARPA-funded project (26.9 million dollars) aims to build "biased agonist" psychedelics that keep antidepressant effects in mice without a trip, unproven in humans.
• ●A personal or family history of schizophrenia, bipolar disorder, or borderline personality disorder are, in Roth's view, reasons to generally avoid psychedelics.
• ●Roth argues AI has largely solved drug design for a known target; the unsolved problem is picking which of 26,000 human genome targets to pursue.
• ●Psychedelic experiences often rank among people's most meaningful life events, a quality Roth says is unexplained since these drugs barely affect norepinephrine.